← All trials
NCT04012294
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2019
- Primary completion
- Dec 31, 2019
- Completion date
- Feb 28, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Instituto Nacional de Cardiologia Ignacio ChavezLead sponsor
- Instituto Nacional de RehabilitacionCollaborator
- Instituto Nacional de Cardiologia Ignacio ChavezOverall official - principal investigator
- Instituto Nacional de Cardiologia Ignacio ChavezReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.